Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
Humans infected with SARS-CoV-2 may develop COVID-19, which manifests across a wide spectrum of clinical severity ranging from mild upper respiratory tract illnesses to diffuse viral pneumonia, causing acute respiratory failure. Many therapies have been tested for their efficacy in treating COVID-19...
Guardado en:
Autores principales: | Maamoun Basheer, Elias Saad, Dorin Shlezinger, Nimer Assy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/39c341d34bd845b8a70eddb50ac35c47 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Convalescent Plasma for the Treatment of Severe COVID-19
por: Franchini M, et al.
Publicado: (2021) -
Effectiveness of convalescent plasma therapy in eight non-intubated coronavirus disease 2019 patients in Indonesia: a case series
por: Theresia Monica Rahardjo, et al.
Publicado: (2021) -
Convalescent plasma therapy in patients with coronavirus disease-19 – One year after: A brief review
por: Mariela Irabien-Zúñiga, et al.
Publicado: (2021) -
SEIR Mathematical Model of Convalescent Plasma Transfusion to Reduce COVID-19 Disease Transmission
por: Hennie Husniah, et al.
Publicado: (2021) -
Convalescent plasma therapy in an immunocompromised patient with multiple COVID‐19 flares: a case report
por: Frini Karaolidou, et al.
Publicado: (2021)